QureBio Ltd. to Present its Q-1802 Clinical Phase Ⅰ Data at 2023 ASCO-GI Meetings
Details : Q-1802, a humanized bispecific antibody, is the first FDA-approved and the first enter clinical trial Claudin18.2/PD-L1 bispecific antibody，as well as the first to present clinical data at ASCO annual meeting.
Product Name : Q-1802
Product Type : Antibody
Upfront Cash : Inapplicable
December 20, 2022
QureBio Ltd. to Showcase its Q-1802 Clinical Advances at 2022 ASCO Annual Meetings
Details : In animal model studies, Q-1802 demonstrates both superior anti-tumor activities and excellent safety profiles. It recruits multiple immune mechanisms to kill tumor cells, offering a novel therapeutic opportunity for Claudin18.2 positive solid tumors.
Product Name : Q-1802
Product Type : Antibody
Upfront Cash : Inapplicable
May 31, 2022
Lead Product(s) : Q-1802
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Q-1802 is the lead candidate in QureBio's pipeline and is the first bispecific antibody against PD-L1 and Claudin18.2 to be studied in a U.S. clinical trial.
Product Name : Q-1802
Product Type : Antibody
Upfront Cash : Inapplicable
February 03, 2021
Lead Product(s) : Q-1802
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
